The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma
Open accessAbstract
&NA; Glioblastomas (GBMs) are highly aggressive brain tumors with a very grim prognosis even after multi‐modal therapeutic regimens. Conventional chemotherapeutic agents frequently lead to drug resistance and result in severe toxicities to non‐cancerous tissues. Resveratrol (RES), a natural polyphenol with pleiotropic health benefits, has proven chemopreventive effects in all the stages of cancer including initiation, promotion and progression. However, the poor physico‐chemical properties of RES severely limit its use as a free drug. In this study, RES was loaded into PEGylated liposomes (RES‐L) to counter its drawbacks as a free drug. Since transferrin receptors (TfRs) are up‐regulated in GBM, the liposome surface was modified with transferrin moieties (Tf‐RES‐L) to make them cancer cell‐specific. The liposomal nanomedicines developed in this project were aimed at enhancing the physico‐chemical properties of RES and exploiting the passive and active targeting capabilities of liposomes to effectively treat GBM. The RES‐L were stable, had a good drug‐loading capacity, prolonged drug‐release in vitro and were easily scalable. Flow cytometry and confocal microscopy were used to study the association with, and internalization of, Tf‐L into U‐87 MG cells. The Tf‐RES‐Ls were significantly more cytotoxic and induced higher levels of apoptosis accompanied by activation of caspases 3/7 in GBM cells when compared to free RES or RES‐L. The ability of RES to arrest cells in the S‐phase of the cell cycle, and selectively induce production of reactive oxygen species in cancer cells were probably responsible for its cytotoxic effects. The therapeutic efficacy of RES formulations was evaluated in a subcutaneous xenograft mouse model of GBM. A tumor growth inhibition study and a modified survival study showed that Tf‐RES‐Ls were more effective than other treatments in their ability to inhibit tumor growth and improve survival in mice. Overall, the liposomal nanomedicines of RES developed in this project exhibited favorable in vitro and in vivo efficacies, which warrant their further investigation for the treatment of GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Yang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358696 · Cited by 3,253
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationHigh Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
ROS stress in cancer cells and therapeutic implications
Pelicano, H., Carney, D., & Huang, P. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.004 · Cited by 2,006
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., & Walle, U. K. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000885 · Cited by 1,880
Ostrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou223 · Cited by 1,718
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Persistent oxidative stress in cancer
Toyokuni, S., Okamoto, K., Yodoi, J., & Hiai, H. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01368-b · Cited by 1,219
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
The signaling mechanism of ROS in tumor progression
Wu, W.-S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9037-8 · Cited by 752
Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 634
Structure of the human transferrin receptor-transferrin complex
Cheng, Y., Zak, O., Aisen, P., Harrison, S. C., & Walz, T. (2004) · Cell · doi:10.1016/s0092-8674(04)00130-8 · Cited by 571
Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., & Ducharme, M. P. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033340 · Cited by 480
Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery
Gullotti, E., & Yeo, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900090z · Cited by 473
Resveratrol: French Paradox Revisited
Catalgol, B., Batirel, S., Taga, Y., & Ozer, N. K. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00141 · Cited by 449
Inhibition of cancer growth by resveratrol is related to its low bioavailability
Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., & Estrela, J. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00911-5 · Cited by 388
R. Neves, A., Lucio, M., L.C. Lima, J., & Reis, S. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799945085 · Cited by 313
Torchilin, V. P., Levchenko, T. S., Lukyanov, A. N., Khaw, B. A., Klibanov, A. L., Rammohan, R., Samokhin, G. P., & Whiteman, K. R. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2728(01)00165-7 · Cited by 271
Self-citationMeng, J., Guo, F., Xu, H., Liang, W., Wang, C., & Yang, X.-D. (2016) · Scientific Reports · doi:10.1038/srep22390 · Cited by 236
Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells
MIKI, H., UEHARA, N., KIMURA, A., SASAKI, T., YURI, T., YOSHIZAWA, K., & TSUBURA, A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1325 · Cited by 225
Glioblastoma Heterogeneity and Cancer Cell Plasticity
Friedmann-Morvinski, D. (2014) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2014011777 · Cited by 225
Local clustering of transferrin receptors promotes clathrin-coated pit initiation
Liu, A. P., Aguet, F., Danuser, G., & Schmid, S. L. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201008117 · Cited by 222
Resveratrol Suppresses the Angiogenesis and Tumor Growth of Gliomas in Rats
Tseng, S.-H., Lin, S.-M., Chen, J.-C., Su, Y.-H., Huang, H.-Y., Chen, C.-K., Lin, P.-Y., & Chen, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0105 · Cited by 217
Filippi-Chiela, E. C., Villodre, E. S., Zamin, L. L., & Lenz, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020849 · Cited by 181
Transferrin As A Targeting Ligand for Liposomes and Anticancer Drugs
Singh, M. (1999) · Current Pharmaceutical Design · doi:10.2174/138161280506230110111312 · Cited by 181
Resveratrol Induces Premature Senescence in Lung Cancer Cells via ROS-Mediated DNA Damage
Luo, H., Yang, A., Schulte, B. A., Wargovich, M. J., & Wang, G. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060065 · Cited by 176
Yang, Y., Chang, Y., Huang, P., Chiou, G., Tseng, L., Chiou, S., Chen, M., Chen, M., Shih, Y., Chang, C., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22806 · Cited by 148
Use of the post-insertion method for the formation of ligand-coupled liposomes.
Allen, T. M., Sapra, P., & Moase, E. H. (2002) · PubMed · Cited by 137
Ganapathy, S., Chen, Q., Singh, K. P., Shankar, S., & Srivastava, R. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015627 · Cited by 133
Transferrin Receptor 2 Is Frequently and Highly Expressed in Glioblastomas
Calzolari, A., Larocca, L. M., Deaglio, S., Finisguerra, V., Boe, A., Raggi, C., Ricci-Vitani, L., Pierconti, F., Malavasi, F., Maria, R. D., et al. (2010) · Translational Oncology · doi:10.1593/tlo.09274 · Cited by 132
Intracellular delivery of nanocarriers and targeting to subcellular organelles
Jhaveri, A. M., & Torchilin, V. P. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1086745 · Cited by 131
Self-citationGu, S., Chen, C., Jiang, X., & Zhang, Z. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.01.005 · Cited by 130
Transferrin modified PEG-PLA-resveratrol conjugates: In vitro and in vivo studies for glioma
Guo, W., Li, A., Jia, Z., Yuan, Y., Dai, H., & Hong-xiu, L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.034 · Cited by 122
Vijayakumar, M. R., Vajanthri, K. Y., Balavigneswaran, C. K., Mahto, S. K., Mishra, N., Muthu, M. S., & Singh, S. K. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.05.037 · Cited by 122
Mohan, A., Narayanan, S., Sethuraman, S., & Krishnan, U. M. (2014) · BioMed Research International · doi:10.1155/2014/424239 · Cited by 115
Clark, P. A., Bhattacharya, S., Elmayan, A., Darjatmoko, S. R., Thuro, B. A., Yan, M. B., van Ginkel, P. R., Polans, A. S., & Kuo, J. S. (2016) · Journal of neurosurgery · doi:10.3171/2016.1.jns152077 · Cited by 107
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
Liu, A., Hou, C., Chen, H., Zong, X., & Zong, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00016 · Cited by 105
Catania, A., Barrajón‐Catalán, E., Nicolosi, S., Cicirata, F., & Micol, V. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2667-y · Cited by 104
Kawamoto, M., Horibe, T., Kohno, M., & Kawakami, K. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-359 · Cited by 81
Balachandran, V., Haritha, N. H., Vijayakurup, V., Shabna, A., Shah, S., Krishna, A., Pillai, K. S., Thankachan, S., & Anto, R. J. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.61 · Cited by 80
Satō, A., Okada, M., Shibuya, K., Watanabe, E., Seino, S., Suzuki, K., Narita, Y., Shibui, S., Kayama, T., & Kitanaka, C. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.04.004 · Cited by 79
Sawant, R. R., Jhaveri, A. M., Koshkaryev, A., Zhu, L., Qureshi, F., & Torchilin, V. P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300633f · Cited by 71
Self-citationMohan, A., Narayanan, S., Gopalan, B., Sethuraman, S., & Krishnan, U. M. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.11.017 · Cited by 68
Dual ligand immunoliposomes for drug delivery to the brain
Loureiro, J. A., Gomes, B., Fricker, G., Cardoso, I., Ribeiro, C. A., Gaiteiro, C., Coelho, M. A. N., Pereira, M. D. C., & Rocha, S. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.06.067 · Cited by 65
Crépin, R., Goenaga, A.-L., Jullienne, B., Bougherara, H., Legay, C., Benihoud, K., Marks, J. D., & Poul, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0938 · Cited by 59
Castino, R., Pucer, A., Veneroni, R., Morani, F., Peracchio, C., Lah, T. T., & Isidoro, C. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf104917q · Cited by 53
Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis
Mitchell, M. J., Webster, J., Chung, A., Guimarães, P. P. G., Khan, O. F., & Langer, R. (2017) · Nature Communications · doi:10.1038/ncomms14179 · Cited by 34
Kim, S. H., Adhikari, B. B., Cruz, S., Schramm, M. P., Vinson, J. A., & Narayanaswami, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135130 · Cited by 33
Cited by
Current trends and challenges in cancer management and therapy using designer nanomaterials
Navya, P. N., Kaphle, A., Srinivas, S. P., Bhargava, S. K., Rotello, V. M., & Daima, H. K. (2019) · Nano Convergence · doi:10.1186/s40580-019-0193-2 · Cited by 672
Composition design and medical application of liposomes
Li, M., Du, C., Guo, N., Teng, Y., Meng, X., Sun, H., Li, S., Yu, P., & Galons, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.007 · Cited by 555
Improving the bioavailability of phenolic compounds by loading them within lipid-based nanocarriers
Faridi Esfanjani, A., Assadpour, E., & Jafari, S. M. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.04.002 · Cited by 405
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Metadata
- Authors
- Jhaveri, A., Deshpande, P., Pattni, B., & Torchilin, V.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 277
- Pages
- 89-101
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2791841262
- Cited by
- 294
- References
- 62
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.